UiPath
PATH
$13.32
-1.19%
UiPath, Inc. is an enterprise software company that provides an end-to-end automation platform combining robotic process automation (RPA), API integration, and artificial intelligence to automate repetitive business tasks such as claims processing, employee onboarding, and invoice-to-cash workflows across industries. The company is a recognized leader in the RPA market, but it is repositioning itself as an agentic AI orchestration platform, seeking to defend its franchise against a wave of AI-native competitors and hyperscaler automation tools. The current investor narrative is dominated by the tension between UiPath's improving profitability and its decelerating growth, with the stock having slid 24% after Q2 earnings despite strong results, which bulls argue was an overreaction. Management's raised outlook and the emerging agentic AI opportunity have created a polarized debate: some see a cheap, cash-generative turnaround story, while others fear that generative AI could commoditize traditional RPA and cap long-term growth.…
PATH
UiPath
$13.32
Related headlines
Investment Opinion: Should I buy PATH Today?
We assign a Hold rating on PATH. The core thesis is that UiPath is a cash-generative, profitable company trading at a deep discount to its historical valuation, but decelerating growth and competitive pressures limit near-term upside. The analyst consensus of Hold (mean 2.86) and average target of $15.50 (15.0% upside) align with this balanced view.
Supporting evidence includes: 1) Forward PE of 14.64x, well below the trailing 24.21x and historical 45-64x range; 2) Revenue growth of 13.4% YoY, positive but decelerating; 3) Net margin of 8.8% and operating margin of 7.7%, a significant turnaround from negative levels; 4) Free cash flow of $362.96M TTM, providing financial flexibility; and 5) PS ratio of 4.21x, near the low end of its historical range. These metrics suggest the stock is undervalued relative to its own history, but the growth slowdown justifies a discount to high-growth peers.
Key risks that could invalidate the thesis include: 1) Continued revenue deceleration below 10% YoY, which would pressure the multiple; 2) Gross margin falling below 80%, impacting profitability; and 3) Failure to gain traction in agentic AI, allowing competitors to capture market share. The rating would upgrade to Buy if revenue growth reaccelerates above 15% or if the forward PE compresses below 12x with improving margins. It would downgrade to Sell if revenue growth turns negative or if free cash flow declines significantly. Relative to its history and peers, PATH appears undervalued, but the market is pricing in persistent growth challenges.
Sign up to view all
PATH 12-Month Price Forecast
UiPath presents a balanced risk/reward profile. The company has successfully transitioned to profitability, with net income of $36.09M in Q2 and a strong balance sheet, but revenue growth has slowed to 13.4% and gross margins are compressing. The valuation is attractive on a forward PE basis (14.64x) and PS (4.21x), but the market is pricing in skepticism about growth durability. The agentic AI pivot is a potential catalyst, but execution risks are high. We would upgrade to bullish if revenue growth reaccelerates above 15% and margins stabilize; we would downgrade to bearish if growth falls below 10% or if competitive pressures intensify.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on UiPath's 12-month outlook, with a consensus price target around $15.50 and implied upside of +16.4% versus the current price.
Average Target
$15.50
0 analysts
Implied Upside
+16.4%
vs. current price
Analyst Count
—
covering this stock
Price Range
$10 - $23
Analyst target range
UiPath is covered by 17 analysts, with a consensus recommendation of 'Hold' and a recommendation mean of 2.86 (where 1 is Strong Buy and 5 is Strong Sell). The average target price is $15.50, which implies approximately 15.0% upside from the current price of $13.48. The consensus is neutral to slightly bearish, with no strong buy ratings and a recent downgrade from DA Davidson to Underperform on September 28, 2026. The distribution of ratings is skewed toward Hold, with several firms maintaining neutral or market perform ratings, indicating that analysts are waiting for clearer signs of sustainable growth acceleration before turning more positive. The target price range is wide, from a low of $10.00 to a high of $23.00, reflecting significant disagreement about the company's future. The high target of $23.00 implies a 70.6% upside and likely assumes that UiPath successfully pivots to agentic AI, reaccelerates growth, and expands margins, while the low target of $10.00 suggests a 25.8% downside and prices in continued deceleration, competitive pressures, and margin compression. The wide spread signals high uncertainty, which is typical for a company in transition. Recent institutional ratings show a mix of holds and buys, with Needham maintaining a Buy rating, but the overall trend has been toward caution, as evidenced by the DA Davidson downgrade. This lack of strong conviction may keep the stock range-bound until the next earnings report provides clarity on growth and AI traction.
Bulls vs Bears: PATH Investment Factors
The bull case rests on UiPath's successful profitability turnaround, fortress balance sheet, and deeply discounted valuation, which could attract value-oriented investors. However, the bear case highlights decelerating growth, gross margin compression, and competitive threats that may cap long-term upside. Currently, the bear evidence appears slightly stronger given the 13.4% revenue growth slowdown and cautious analyst sentiment, but the valuation and cash flow provide a margin of safety. The single most important tension is whether the agentic AI pivot can reaccelerate growth before traditional RPA commoditizes; if it does, the stock could re-rate significantly, but if not, it may remain range-bound.
Bullish
- Profitability inflection with margin expansion: Q2 FY2027 net income swung to $36.09M (8.8% net margin) from a $22.56M loss a year ago, while operating margin improved to 7.7% from -5.6%. This demonstrates that UiPath's cost discipline is translating into sustainable profitability, a key pillar for a re-rating.
- Deeply discounted valuation vs. history and peers: The forward PE of 14.64x is well below the trailing PE of 24.21x and the stock's historical PE range (45-64x in recent quarters). The PS ratio of 4.21x is near the bottom of its historical range (low of 12.89x in Q1 FY2027), suggesting the market is pricing in excessive pessimism.
- Fortress balance sheet with strong cash generation: UiPath holds $608.89M in cash with a debt-to-equity ratio of just 0.039 and a current ratio of 2.48. It generated $362.96M in trailing free cash flow and $30.70M in operating cash flow in Q2, providing ample flexibility for buybacks ($24.75M in Q2) and AI investments.
- Agentic AI pivot could reignite growth: The company is repositioning its platform for agentic AI orchestration, a market projected to be the biggest tech trend of 2026. If successful, this could reverse the deceleration from 13.4% YoY growth and open a larger TAM, as highlighted by multiple analyst notes.
Bearish
- Decelerating revenue growth: Q2 FY2027 revenue grew 13.4% YoY to $410.26M, a sharp slowdown from prior periods and below the 15%+ growth typical of premium software companies. Sequential revenue has been flat to down (Q1 $418.38M, Q4 $481.11M), indicating a lack of near-term acceleration.
- Gross margin compression: Gross margin declined to 80.36% in Q2 from 82.20% a year ago, reflecting a mix shift toward lower-margin subscription services and rising cloud costs. If this trend continues, it could pressure operating leverage and limit earnings growth.
- Analyst consensus is cautious: With a recommendation mean of 2.86 (Hold) and a recent downgrade to Underperform by DA Davidson, analyst sentiment is neutral to negative. The wide target range ($10-$23) signals high uncertainty, and the lack of strong buy ratings suggests limited near-term catalysts.
- Competitive threats from AI-native and hyperscalers: Generative AI and agentic AI could commoditize traditional RPA, while hyperscalers like Microsoft and ServiceNow integrate automation into their suites. UiPath's 13.4% growth may struggle against these larger, faster-growing competitors.
PATH Technical Analysis
UiPath's stock is in a recovery phase within a broader downtrend, with the current price of $13.48 sitting at 40.2% of its 52-week range (low of $9.20 to high of $19.84). The 1-year price change of -27.17% confirms that the longer-term trend remains negative, but the stock has rebounded sharply from its lows, gaining 43.71% over the past six months. This positioning suggests that while the stock is not near overextended highs, it has already priced in a significant recovery from the depths of pessimism. The 3-month change of +15.41% and 6-month change of +43.71% indicate that momentum has been building, but the 1-month change of -0.66% shows a recent stall. This divergence—strong medium-term gains but flat short-term performance—suggests the stock is consolidating after a sharp run-up, potentially forming a base before the next directional move. The relative strength versus SPY over 3 months (+12.28%) and 6 months (+29.12%) highlights that UiPath has been outperforming the market recently, even as its 1-year relative strength remains deeply negative at -43.17%. Key technical levels are clear: support rests at the 52-week low of $9.20, while resistance is at the 52-week high of $19.84. A breakout above $19.84 would signal a full trend reversal and likely attract momentum buyers, whereas a breakdown below $9.20 would confirm the bearish longer-term trend and could trigger further selling. With a beta of 1.01, the stock moves roughly in line with the broader market, implying that its volatility is not excessively high relative to SPY, which may appeal to investors seeking market-like risk with idiosyncratic upside.
Beta
1.01
1.01x market volatility
Max Drawdown
-51.4%
Largest decline past year
52-Week Range
$9-$20
Price range past year
Annual Return
-21.9%
Cumulative gain past year
| Period | PATH Return | S&P 500 |
|---|---|---|
| 1m | -3.1% | +1.8% |
| 3m | +11.6% | +3.5% |
| 6m | +25.5% | +11.2% |
| 1y | -21.9% | +19.1% |
| ytd | -16.1% | +14.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
PATH Fundamental Analysis
UiPath's revenue trajectory shows a company that is still growing but at a decelerating pace. The most recent quarter (Q2 FY2027, ended July 31, 2026) reported revenue of $410.26 million, up 13.42% year-over-year, which is a slowdown from the prior year's growth rates. The multi-quarter trend reveals that revenue has been relatively flat sequentially, with Q1 at $418.38 million and Q4 at $481.11 million, indicating that the company is not accelerating. Subscription services, the largest segment at $266.07 million, is the primary growth driver, while license revenue of $123.84 million and professional services of $39.45 million are smaller contributors. The deceleration is a concern for a software company, but the fact that growth remains positive and the company is profitable may provide a floor for the stock. Profitability has improved markedly, with Q2 net income of $36.09 million and a net margin of 8.80%, a significant turnaround from the net loss of $22.56 million in the year-ago quarter. Gross margin remains robust at 80.36%, though it has compressed slightly from 82.20% a year ago, likely due to mix shift toward subscription services and increased cloud costs. Operating margin stands at 7.70%, up from -5.58% in the prior-year period, reflecting disciplined cost management, particularly in R&D and sales and marketing. The balance sheet is exceptionally strong, with a debt-to-equity ratio of just 0.039 and a current ratio of 2.48, indicating ample liquidity. Free cash flow for the trailing twelve months is $362.96 million, and the company generated $30.70 million in operating cash flow in Q2 alone, despite a $103.36 million working capital drag. With $608.89 million in cash and no significant debt, UiPath has the financial flexibility to fund growth internally, invest in AI capabilities, and continue share repurchases, which totaled $24.75 million in Q2.
Quarterly Revenue
$410256000.0B
2026-07
Revenue YoY Growth
+13.4%
YoY Comparison
Gross Margin
80.4%
Latest Quarter
Free Cash Flow
$362957000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is PATH Overvalued?
Because UiPath is profitable with positive net income of $36.09 million in the most recent quarter, the PE ratio is the primary valuation metric. The trailing PE is 24.21x, while the forward PE is 14.64x, implying that the market expects earnings to grow substantially over the next year. This large gap between trailing and forward multiples suggests that analysts anticipate significant earnings acceleration, likely driven by operating leverage and continued revenue growth. On a price-to-sales basis, UiPath trades at 4.21x, which is relatively low for a software company with 80%+ gross margins, but the PEG ratio of -0.05 is distorted by negative historical earnings growth and is not meaningful. Compared to the broader software infrastructure industry, UiPath's forward PE of 14.64x is at a discount to many high-growth peers, but its PS ratio of 4.21x is also below the sector average, reflecting the market's skepticism about its growth durability. The EV/Sales ratio of 3.31x and EV/EBITDA of 50.89x further illustrate the mixed picture: the company is cheap on sales but expensive on EBITDA due to its relatively low operating margins. Historically, UiPath's PS ratio has ranged from a high of 125x in late 2021 to a low of 12.89x in Q1 FY2027, and the current 4.21x is near the bottom of that range. Similarly, the PE ratio has swung wildly due to fluctuating profitability, but the current 24.21x is well below the 45.57x seen in Q2 FY2027 and the 64.38x in Q1 FY2027. This suggests that the stock is priced for pessimism, and any positive surprise on growth or margins could lead to multiple expansion.
PE
24.2x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 11x~96x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
50.9x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are moderate but manageable. The company's debt-to-equity ratio of 0.039 and current ratio of 2.48 indicate a strong balance sheet with minimal leverage, reducing solvency risk. However, gross margin compression from 82.20% to 80.36% YoY and a deceleration in revenue growth to 13.4% could pressure profitability if the mix shift toward subscription services continues. Additionally, the company's reliance on a single product category (RPA) and a concentrated customer base in the Americas exposes it to regional economic downturns and competitive displacement.
Market and competitive risks are significant. The stock's beta of 1.01 suggests it moves with the broader market, but its 1-year relative underperformance of -43.17% versus SPY highlights idiosyncratic weakness. Valuation compression risk is elevated given the forward PE of 14.64x, which, while low historically, could contract further if growth stalls. Competitive threats from AI-native startups and hyperscalers like Microsoft and ServiceNow could erode UiPath's market share, and the recent DA Davidson downgrade to Underperform reflects these concerns. Regulatory headwinds, such as data privacy laws affecting automation, could also impact adoption.
The worst-case scenario involves a continued deceleration in revenue growth, margin erosion, and failed AI pivot, leading to multiple compression. In this scenario, the stock could retest its 52-week low of $9.20, representing a 31.8% downside from the current $13.48. The analyst low target of $10.00 implies a 25.8% decline, and the historical max drawdown of -51.37% underscores the potential severity. Investors could lose approximately 32% to 26% from current levels in this adverse scenario, with further downside if the company reports disappointing earnings or loses key customers.
FAQ
The key risks include: 1) Financial risk: revenue growth deceleration to 13.4% YoY and gross margin compression to 80.36% could pressure profitability; 2) Competitive risk: AI-native startups and hyperscalers like Microsoft and ServiceNow could erode market share; 3) Macro risk: beta of 1.01 means the stock is sensitive to market downturns, and enterprise software spending could slow; 4) Company-specific risk: failure to successfully pivot to agentic AI could cap long-term growth. The most severe risk is a growth stall leading to multiple compression, with downside to $9.20 (32% decline).
Our 12-month forecast has three scenarios: Bull case (25% probability) targets $19-$23, assuming successful AI pivot and revenue reacceleration; Base case (55% probability) targets $14-$17, assuming steady mid-teens growth and margin stability; Bear case (20% probability) targets $9.20-$10.00, assuming growth deceleration and competitive pressures. The base case is most likely, with the stock expected to trade around the analyst average target of $15.50. The key assumption is that revenue growth remains between 12-15% and operating margins stay in the 7-9% range.
PATH appears undervalued relative to its own history and peers. The forward PE of 14.64x is well below the trailing 24.21x and the historical range of 45-64x. The PS ratio of 4.21x is near the low end of its historical range (low of 12.89x in Q1 FY2027). Compared to high-growth software peers, PATH trades at a discount, reflecting skepticism about its growth durability. The market is pricing in mid-teens growth and stable margins; if the company exceeds these expectations, the multiple could expand. However, if growth stalls, the stock could remain cheap for a reason.
PATH is a Hold-rated stock with a balanced risk/reward profile. The average analyst target of $15.50 implies 15% upside, and the forward PE of 14.64x is attractive compared to its historical range. However, revenue growth has decelerated to 13.4% YoY, and gross margins are compressing, which could limit upside. The biggest downside risk is a retest of the 52-week low of $9.20, representing a 32% decline. For risk-tolerant investors with a long-term horizon, PATH could be a good buy on dips, but it is not a compelling buy at current levels given the growth uncertainty.
PATH is more suitable for long-term investment (minimum 2-3 years) given its turnaround nature and the time needed for the agentic AI pivot to materialize. The stock has a beta of 1.01, indicating market-like volatility, and pays no dividend, so it is not an income play. Short-term trading is risky due to the wide analyst target range ($10-$23) and earnings-driven volatility. The company's strong balance sheet and cash flow provide a margin of safety for long-term holders, but near-term catalysts are limited. A suggested holding period of at least 2 years allows for the AI strategy to gain traction and for margins to improve.